The companies did not provide detailed data for Tezspire, however, and William Blair’s Matt Phipps said in a note he does not ...

While the final decision is set for next month, biotech player Neurizon’s (ASX:NUZ) hopes have been lifted with a view ...

Results from the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps showed that AstraZeneca (AZN) and ...

Targets the reduction in CABG-related bleeding severity due to the blood thinning drug, ticagrelor – a major unmet medical need in heart attack ...

A Covid vaccine compensation scheme could be set up after thousands claimed they have been left disabled as a result of the AstraZeneca jab, The Telegraph has learnt. The Health Secretary is ...

Before joining BeiGene, Yin spent 15 years with AstraZeneca, having served in various posts at the British drugmaker, including as head of its oncology business in China. Yin has been detained by ...

(IN BRIEF) AstraZeneca presented significant advancements in the prevention of infectious diseases at IDWeek 2024, showcasing its dedication to addressing respiratory infections caused by RSV, hMPV, ...

New Developer Platform delivers more flexibility and control to unlock new workflows, applications, and material options. New bulk material pricing brings prices as low as $35 per liter for SLA ...

FluMist is an efficacious and safely tolerated intranasal influenza vaccine. FluMist has gained approval from the FDA for self-administration by patients aged 18-49. FluMist is the first influenza ...

In an interview with China Daily, Sharon Barr, executive vice-president of biopharmaceuticals R&D at AstraZeneca, said the company's presence in Shanghai is absolutely critical to achieving its ...